SLC5A2 and type 2 diabetes mellitus: A greater understanding of the efficacy and safety profile of combination therapy with an SGLT2 inhibitor and other anti-hyperglycaemic agent versus monotherapy with each agent in the combination will aid clinicians when deciding on pharmacotherapy for their newly diagnosed type 2 diabetes patients.